Supplementary Information
Supplementary Figure 1. Flow diagram of included study
Supplementary Table 1. Baseline characteristics of 11 individuals
Supplementary Table 2. Changes in laboratory values due to treatment.
Supplementary Table 3. Summary of analyzed case reports on the
administration of Anti-IL-5 for EGPA.